US6861511B1
(en)
*
|
1986-06-04 |
2005-03-01 |
Bayer Corporation |
Detection and quantification of neu related proteins in the biological fluids of humans
|
WO1989006692A1
(en)
|
1988-01-12 |
1989-07-27 |
Genentech, Inc. |
Method of treating tumor cells by inhibiting growth factor receptor function
|
ES2166352T3
(es)
*
|
1989-08-04 |
2002-04-16 |
Schering Ag |
Dominio externo de c-erbb-2:gp75.
|
US7282345B1
(en)
*
|
1989-08-04 |
2007-10-16 |
Schering Ag |
C-erbB-2 external domain: GP75
|
ES2070492T3
(es)
*
|
1990-01-26 |
1995-06-01 |
Washington Res Found |
Reactividad inmunitaria para oncogenes expresados activos para diagnostico y tratamiento de estados malignos.
|
CA2037440A1
(en)
*
|
1990-03-02 |
1991-09-03 |
Gregory D. Plowman |
Her3: a novel egf receptor homolog
|
US5578482A
(en)
*
|
1990-05-25 |
1996-11-26 |
Georgetown University |
Ligand growth factors that bind to the erbB-2 receptor protein and induce cellular responses
|
US5571894A
(en)
*
|
1991-02-05 |
1996-11-05 |
Ciba-Geigy Corporation |
Recombinant antibodies specific for a growth factor receptor
|
AU662311B2
(en)
*
|
1991-02-05 |
1995-08-31 |
Novartis Ag |
Recombinant antibodies specific for a growth factor receptor
|
US7285531B1
(en)
|
1991-04-10 |
2007-10-23 |
Acorda Therapeutics, Inc. |
Method for prophylaxis or treatment of a nervous system, pathophysiological condition involving a glial growth factor sensitive cell by administration of a glial growth factor
|
US7135456B1
(en)
|
1991-04-10 |
2006-11-14 |
Acorda Therapeutics, Inc. |
Glial mitogenic factors, their preparation and use
|
US7094749B1
(en)
|
1991-04-10 |
2006-08-22 |
Acorda Therapeutics, Inc. |
Glial mitogenic factors, their preparation and use
|
US7319019B1
(en)
|
1991-04-10 |
2008-01-15 |
Acorda Therapeutics, Inc. |
Glial mitogenic factors lacking an N-terminal signal sequence
|
US7115554B1
(en)
|
1993-05-06 |
2006-10-03 |
Acorda Therapeutics, Inc. |
Methods of increasing myotube formation or survival or muscle cell mitogenesis differentiation or survival using neuregulin GGF III
|
US5530109A
(en)
|
1991-04-10 |
1996-06-25 |
Ludwig Institute For Cancer Research |
DNA encoding glial mitogenic factors
|
US5939531A
(en)
*
|
1991-07-15 |
1999-08-17 |
Novartis Corp. |
Recombinant antibodies specific for a growth factor receptor
|
DE4129533A1
(de)
*
|
1991-09-05 |
1993-03-11 |
Max Planck Gesellschaft |
Mutierter wachstumsfaktorrezeptor als arzneimittel und seine verwendung zur behandlung von krebs
|
WO1993010814A1
(en)
*
|
1991-11-29 |
1993-06-10 |
Viagene, Inc. |
Anti-cancer immunotherapeutic vector constructs
|
US7037888B1
(en)
|
1992-04-03 |
2006-05-02 |
Acorda Therapeutics, Inc. |
Methods for treating muscle diseases and disorders
|
GB9217316D0
(en)
*
|
1992-08-14 |
1992-09-30 |
Ludwig Inst Cancer Res |
Schwann cell mitogenic factor,its preparation and use
|
CA2103323A1
(en)
*
|
1992-11-24 |
1994-05-25 |
Gregory D. Plowman |
Her4 human receptor tyrosine kinase
|
US5869445A
(en)
*
|
1993-03-17 |
1999-02-09 |
University Of Washington |
Methods for eliciting or enhancing reactivity to HER-2/neu protein
|
US5801005A
(en)
*
|
1993-03-17 |
1998-09-01 |
University Of Washington |
Immune reactivity to HER-2/neu protein for diagnosis of malignancies in which the HER-2/neu oncogene is associated
|
US6953573B1
(en)
|
1993-03-17 |
2005-10-11 |
University Of Washington |
Compounds for eliciting or enhancing immune reactivity to HER-2/neu protein for prevention or treatment of malignancies in which the HER-2/neu oncogene is associated
|
US8956621B2
(en)
|
1994-11-08 |
2015-02-17 |
The Trustees Of The University Of Pennsylvania |
Compositions and methods for treatment of cervical dysplasia
|
US7794729B2
(en)
|
1994-11-08 |
2010-09-14 |
The Trustees Of The University Of Pennsylvania |
Methods and compositions for immunotherapy of cancer
|
US7820180B2
(en)
*
|
2004-09-24 |
2010-10-26 |
The Trustees Of The University Of Pennsylvania |
Listeria-based and LLO-based vaccines
|
US20070264279A1
(en)
*
|
1994-11-08 |
2007-11-15 |
Claudia Gravekamp |
Compositions and methods comprising a MAGE-b antigen
|
US8791237B2
(en)
*
|
1994-11-08 |
2014-07-29 |
The Trustees Of The University Of Pennsylvania |
Compositions and methods for treatment of non-hodgkins lymphoma
|
US8114414B2
(en)
*
|
1994-11-08 |
2012-02-14 |
The Trustees Of The University Of Pennsylvania |
Compositions and methods for treatment of cervical cancer
|
US6514942B1
(en)
*
|
1995-03-14 |
2003-02-04 |
The Board Of Regents, The University Of Texas System |
Methods and compositions for stimulating T-lymphocytes
|
IT1276662B1
(it)
*
|
1995-04-04 |
1997-11-03 |
Uni Degli Studi Camerino |
Vaccini polinucleotidici
|
US6465623B2
(en)
|
1995-05-02 |
2002-10-15 |
Garvan Institute Of Medical Research |
GDU, a novel signalling protein
|
US6685940B2
(en)
|
1995-07-27 |
2004-02-03 |
Genentech, Inc. |
Protein formulation
|
US6267958B1
(en)
|
1995-07-27 |
2001-07-31 |
Genentech, Inc. |
Protein formulation
|
US6656481B1
(en)
|
1996-09-06 |
2003-12-02 |
Mitsubishi Chemical Corporation |
Vaccinal preparations
|
US7371376B1
(en)
*
|
1996-10-18 |
2008-05-13 |
Genentech, Inc. |
Anti-ErbB2 antibodies
|
US6884435B1
(en)
*
|
1997-01-30 |
2005-04-26 |
Chiron Corporation |
Microparticles with adsorbent surfaces, methods of making same, and uses thereof
|
DK0991403T3
(da)
*
|
1997-01-30 |
2003-07-28 |
Chiron Corp |
Anvendelse af mikropartikler med adsorberet antigen til stimulering af immunresponser
|
US20040202680A1
(en)
*
|
1997-01-30 |
2004-10-14 |
O'hagan Derek |
Microparticles with adsorbent surfaces, methods of making same, and uses thereof
|
ZA9811162B
(en)
|
1997-12-12 |
2000-06-07 |
Genentech Inc |
Treatment with anti-ERBB2 antibodies.
|
US20010023241A1
(en)
*
|
1998-02-04 |
2001-09-20 |
Sliwkowski Mark X. |
Use of heregulin as a growth factor
|
US6541214B1
(en)
*
|
1998-11-13 |
2003-04-01 |
Oregon Heath Science University |
N-terminally truncated HER-2/neu protein as a cancer prognostic indicator
|
US7393823B1
(en)
|
1999-01-20 |
2008-07-01 |
Oregon Health And Science University |
HER-2 binding antagonists
|
US7396810B1
(en)
|
2000-08-14 |
2008-07-08 |
Oregon Health Sciences University |
Compositions and methods for treating cancer by modulating HER-2 and EGF receptors
|
US7625859B1
(en)
|
2000-02-16 |
2009-12-01 |
Oregon Health & Science University |
HER-2 binding antagonists
|
ES2348708T3
(es)
*
|
1999-01-29 |
2010-12-13 |
Corixa Corporation |
Proteinas de fusion de her-2/neu.
|
US7198920B1
(en)
|
1999-01-29 |
2007-04-03 |
Corika Corporation |
HER-2/neu fusion proteins
|
AU5003200A
(en)
|
1999-05-14 |
2000-12-05 |
United States Of America As Represented By The Department Of Veterans Affairs, The |
Isolation and characterization of epidermal growth factor related protein
|
US7049410B2
(en)
*
|
1999-05-14 |
2006-05-23 |
Majumdar Adhip P N |
Antibodies to a novel EGF-receptor related protein (ERRP)
|
US20030086924A1
(en)
*
|
1999-06-25 |
2003-05-08 |
Genentech, Inc. |
Treatment with anti-ErbB2 antibodies
|
ATE437655T1
(de)
|
1999-06-25 |
2009-08-15 |
Genentech Inc |
Humanisierte anti-erbb2 antikörper und behandlung mit anti-erbb2 antikörper
|
JP4579471B2
(ja)
*
|
1999-06-25 |
2010-11-10 |
ジェネンテック, インコーポレイテッド |
抗ErbB2抗体を用いる前立腺癌の処置
|
US20040013667A1
(en)
*
|
1999-06-25 |
2004-01-22 |
Genentech, Inc. |
Treatment with anti-ErbB2 antibodies
|
US6949245B1
(en)
*
|
1999-06-25 |
2005-09-27 |
Genentech, Inc. |
Humanized anti-ErbB2 antibodies and treatment with anti-ErbB2 antibodies
|
US7041292B1
(en)
|
1999-06-25 |
2006-05-09 |
Genentech, Inc. |
Treating prostate cancer with anti-ErbB2 antibodies
|
JP4658423B2
(ja)
*
|
1999-08-03 |
2011-03-23 |
ザ オハイオ ステイト ユニバーシティ |
Her−2タンパク質に対する免疫反応性を増強するためのポリペプチドおよびポリヌクレオチド
|
KR20090024308A
(ko)
*
|
1999-08-27 |
2009-03-06 |
제넨테크, 인크. |
항-ErbB2 항체 투여 치료 방법
|
US20020039583A1
(en)
*
|
1999-09-30 |
2002-04-04 |
Subjeck John R. |
Stress protein compositions and methods for prevention and treatment of cancer and infectious disease
|
JP2003510334A
(ja)
|
1999-09-30 |
2003-03-18 |
コリクサ コーポレイション |
癌及び感染症の予防及び治療のためのストレスタンパク質組成物及び方法
|
US7378096B2
(en)
|
1999-09-30 |
2008-05-27 |
Health Research, Inc. |
Stress protein compositions and methods for prevention and treatment of cancer and infectious disease
|
WO2001055178A2
(en)
|
2000-01-25 |
2001-08-02 |
Genentech, Inc. |
Liv-1 related protein, polynucleotides encoding the same and use thereof for treatment of cancer
|
WO2001062288A1
(en)
*
|
2000-02-25 |
2001-08-30 |
The Regents Of The University Of California |
Membrane estrogen receptor-directed therapy in breast cancer
|
US9012141B2
(en)
|
2000-03-27 |
2015-04-21 |
Advaxis, Inc. |
Compositions and methods comprising KLK3 of FOLH1 antigen
|
EP1303299B1
(en)
*
|
2000-03-29 |
2010-07-28 |
The Trustees of The University of Pennsylvania |
Use of prokaryotic pest-like peptides for enhancing immunogenicity of antigens
|
EP1272647B1
(en)
|
2000-04-11 |
2014-11-12 |
Genentech, Inc. |
Multivalent antibodies and uses therefor
|
AU2001259271A1
(en)
*
|
2000-04-28 |
2001-11-12 |
Millennium Pharmaceuticals, Inc. |
14094, a novel human trypsin family member and uses thereof
|
JP2003534292A
(ja)
*
|
2000-05-19 |
2003-11-18 |
ジェネンテック・インコーポレーテッド |
Erbbアンタゴニスト癌治療に対する有効な応答の可能性を向上させるための遺伝子検出アッセイ
|
US7229623B1
(en)
*
|
2000-08-03 |
2007-06-12 |
Corixa Corporation |
Her-2/neu fusion proteins
|
ES2394293T3
(es)
*
|
2001-02-28 |
2013-01-30 |
Bio Life Science Forschungs- Und Entwicklungsges.M.B.H. |
Vacuna contra cánceres que están asociados con el oncogén HER-2/neu
|
US7700344B2
(en)
*
|
2001-03-26 |
2010-04-20 |
The Trustees Of The University Of Pennsylvania |
Compositions and methods for enhancing the immunogenicity of antigens
|
US8771702B2
(en)
*
|
2001-03-26 |
2014-07-08 |
The Trustees Of The University Of Pennsylvania |
Non-hemolytic LLO fusion proteins and methods of utilizing same
|
WO2002081649A2
(en)
*
|
2001-04-06 |
2002-10-17 |
The Trustees Of The University Of Pennsylvania |
ErbB INTERFACE PEPTIDOMIMETICS AND METHODS OF USE THEREOF
|
EP1399183B1
(en)
|
2001-05-31 |
2010-06-30 |
Novartis Vaccines and Diagnostics, Inc. |
Chimeric alphavirus replicon particles
|
US6997863B2
(en)
*
|
2001-07-25 |
2006-02-14 |
Triton Biosystems, Inc. |
Thermotherapy via targeted delivery of nanoscale magnetic particles
|
US7074175B2
(en)
|
2001-07-25 |
2006-07-11 |
Erik Schroeder Handy |
Thermotherapy via targeted delivery of nanoscale magnetic particles
|
US7731648B2
(en)
*
|
2001-07-25 |
2010-06-08 |
Aduro Biotech |
Magnetic nanoscale particle compositions, and therapeutic methods related thereto
|
US7951061B2
(en)
*
|
2001-07-25 |
2011-05-31 |
Allan Foreman |
Devices for targeted delivery of thermotherapy, and methods related thereto
|
US7098302B2
(en)
|
2001-10-12 |
2006-08-29 |
University Of Vermont And State Agricultural College |
Binding peptides specific for the extracellular domain of ErbB2 and uses therefor
|
EP1513543B1
(en)
|
2002-05-23 |
2010-10-06 |
The Trustees of The University of Pennsylvania |
Fas peptide mimetics and uses thereof
|
JP2006516117A
(ja)
*
|
2002-11-21 |
2006-06-22 |
ジェネンテック・インコーポレーテッド |
抗ErbB2抗体を用いた非悪性疾病または疾患の治療
|
US20040156846A1
(en)
*
|
2003-02-06 |
2004-08-12 |
Triton Biosystems, Inc. |
Therapy via targeted delivery of nanoscale particles using L6 antibodies
|
BRPI0408501A
(pt)
*
|
2003-03-19 |
2006-03-14 |
Biogen Idec Inc |
proteìna de ligação ao receptor nogo
|
AU2004265226A1
(en)
*
|
2003-05-16 |
2005-02-24 |
Receptor Biologix, Inc. |
Intron fusion proteins, and methods of identifying and using same
|
WO2005113596A2
(en)
*
|
2004-05-14 |
2005-12-01 |
Receptor Biologix, Inc. |
Cell surface receptor isoforms and methods of identifying and using the same
|
KR20070034512A
(ko)
|
2004-06-18 |
2007-03-28 |
암브룩스, 인코포레이티드 |
신규 항원-결합 폴리펩티드 및 이의 용도
|
US20110104186A1
(en)
|
2004-06-24 |
2011-05-05 |
Nicholas Valiante |
Small molecule immunopotentiators and assays for their detection
|
PL1776136T3
(pl)
|
2004-06-24 |
2013-03-29 |
Biogen Ma Inc |
Leczenie stanów związanych z demielinizacją
|
JP2008504292A
(ja)
|
2004-06-24 |
2008-02-14 |
ノバルティス ヴァクシンズ アンド ダイアグノスティクス, インコーポレイテッド |
免疫増強用の化合物
|
AU2005294347A1
(en)
*
|
2004-10-05 |
2006-04-20 |
Oregon Health And Science University |
Compositions and methods for treating disease
|
JO3000B1
(ar)
|
2004-10-20 |
2016-09-05 |
Genentech Inc |
مركبات أجسام مضادة .
|
KR20130089280A
(ko)
|
2005-01-21 |
2013-08-09 |
제넨테크, 인크. |
Her 항체의 고정 용량 투여법
|
CA2595395A1
(en)
*
|
2005-02-09 |
2006-08-17 |
Genentech, Inc. |
Inhibiting her2 shedding with matrix metalloprotease antagonists
|
MY152164A
(en)
*
|
2005-02-23 |
2014-08-15 |
Genentech Inc |
Extending time to disease progression or survival in cancer patients
|
WO2006096861A2
(en)
*
|
2005-03-08 |
2006-09-14 |
Genentech, Inc. |
METHODS FOR IDENTIFYING TUMORS RESPONSIVE TO TREATMENT WITH HER DIMERIZATION INHIBITORS (HDIs)
|
US20090170769A1
(en)
*
|
2005-05-13 |
2009-07-02 |
Pei Jin |
Cell surface receptor isoforms and methods of identifying and using the same
|
JP2006316040A
(ja)
|
2005-05-13 |
2006-11-24 |
Genentech Inc |
Herceptin(登録商標)補助療法
|
CA2612394C
(en)
|
2005-06-15 |
2017-02-21 |
The Ohio State University Research Foundation |
Her-2 peptides
|
RS53058B
(en)
|
2005-07-08 |
2014-04-30 |
Biogen Idec Ma Inc. |
SP35 ANTIBODIES AND THEIR APPLICATIONS
|
PE20070207A1
(es)
|
2005-07-22 |
2007-03-09 |
Genentech Inc |
Tratamiento combinado de los tumores que expresan el her
|
US20110223197A1
(en)
|
2005-10-18 |
2011-09-15 |
Novartis Vaccines And Diagnostics Inc. |
Mucosal and Systemic Immunization with Alphavirus Replicon Particles
|
EP1965827B1
(en)
|
2005-12-02 |
2015-02-25 |
Biogen Idec MA Inc. |
Treatment of conditions involving demyelination
|
CA2646891A1
(en)
*
|
2006-03-23 |
2007-09-27 |
Novartis Ag |
Immunopotentiating compounds
|
WO2007109810A2
(en)
*
|
2006-03-23 |
2007-09-27 |
Novartis Ag |
Methods for the preparation of imidazole-containing compounds
|
CA2646539A1
(en)
|
2006-03-23 |
2007-09-27 |
Novartis Ag |
Imidazoquinoxaline compounds as immunomodulators
|
US8268326B2
(en)
*
|
2006-08-15 |
2012-09-18 |
The Trustees Of The University Of Pennsylvania |
Compositions comprising HMW-MAA and fragments thereof, and methods of use thereof
|
EP2977456B1
(en)
*
|
2006-08-15 |
2017-10-25 |
The Trustees Of The University Of Pennsylvania |
Compositions comprising hmw-maa and fragments thereof for treating cancer
|
US8129184B2
(en)
*
|
2006-09-26 |
2012-03-06 |
Cedars-Sinai Medical Center |
Cancer stem cell antigen vaccines and methods
|
US8097256B2
(en)
*
|
2006-09-28 |
2012-01-17 |
Cedars-Sinai Medical Center |
Cancer vaccines and vaccination methods
|
US8128926B2
(en)
|
2007-01-09 |
2012-03-06 |
Biogen Idec Ma Inc. |
Sp35 antibodies and uses thereof
|
BRPI0808418A2
(pt)
|
2007-03-02 |
2014-07-22 |
Genentech Inc |
Predição de resposta a um inibidor de her
|
JP5635399B2
(ja)
|
2007-06-01 |
2014-12-03 |
ザ ヘンリー エム.ジャクソン ファウンデーション フォー ザ アドバンスメント オブ ミリタリー メディスン,インコーポレーテッド |
乳癌再発の予防のためのワクチン
|
US9551033B2
(en)
|
2007-06-08 |
2017-01-24 |
Genentech, Inc. |
Gene expression markers of tumor resistance to HER2 inhibitor treatment
|
DK2171090T3
(da)
*
|
2007-06-08 |
2013-06-10 |
Genentech Inc |
Genekspressionsmarkører for tumorresistens over for HER2-inhibitorbehandling
|
EP2170384B1
(en)
|
2007-07-02 |
2016-04-13 |
Etubics Corporation |
Methods and compositions for producing an adenovirus vector for use with multiple vaccinations
|
TWI472339B
(zh)
|
2008-01-30 |
2015-02-11 |
Genentech Inc |
包含結合至her2結構域ii之抗體及其酸性變異體的組合物
|
US9650639B2
(en)
|
2008-05-19 |
2017-05-16 |
Advaxis, Inc. |
Dual delivery system for heterologous antigens
|
EP2288379A4
(en)
|
2008-05-19 |
2012-08-08 |
Advaxis |
DOUBLE RELEASE SYSTEM FOR HETEROLOGIST ANTIGENE
|
US9017660B2
(en)
|
2009-11-11 |
2015-04-28 |
Advaxis, Inc. |
Compositions and methods for prevention of escape mutation in the treatment of Her2/neu over-expressing tumors
|
BRPI0812682A2
(pt)
|
2008-06-16 |
2010-06-22 |
Genentech Inc |
tratamento de cáncer de mama metastático
|
EP2982695B1
(en)
|
2008-07-09 |
2019-04-03 |
Biogen MA Inc. |
Compositions comprising antibodies to lingo or fragments thereof
|
US9068020B2
(en)
*
|
2008-09-02 |
2015-06-30 |
Cedars-Sinai Medical Center |
CD133 epitopes
|
US20100234283A1
(en)
|
2009-02-04 |
2010-09-16 |
The Ohio State University Research Foundation |
Immunogenic epitopes, peptidomimetics, and anti-peptide antibodies, and methods of their use
|
JP5539411B2
(ja)
|
2009-03-04 |
2014-07-02 |
ザ トラスティーズ オブ ザ ユニバーシティ オブ ペンシルバニア |
血管新生因子を含む組成物およびその使用方法
|
CN102356092B
(zh)
|
2009-03-20 |
2014-11-05 |
霍夫曼-拉罗奇有限公司 |
双特异性抗-her抗体
|
EP2435071A1
(en)
|
2009-05-29 |
2012-04-04 |
F. Hoffmann-La Roche AG |
Modulators for her2 signaling in her2 expressing patients with gastric cancer
|
US10016617B2
(en)
|
2009-11-11 |
2018-07-10 |
The Trustees Of The University Of Pennsylvania |
Combination immuno therapy and radiotherapy for the treatment of Her-2-positive cancers
|
RU2587619C2
(ru)
|
2010-02-18 |
2016-06-20 |
Дженентек, Инк. |
Антагонисты неурегулина и применение их в лечении злокачественного новообразования
|
WO2011146568A1
(en)
|
2010-05-19 |
2011-11-24 |
Genentech, Inc. |
Predicting response to a her inhibitor
|
WO2011149564A1
(en)
|
2010-05-28 |
2011-12-01 |
Tetris Online, Inc. |
Interactive hybrid asynchronous computer game infrastructure
|
CA2798837A1
(en)
|
2010-06-07 |
2011-12-15 |
Pfizer Inc. |
Her-2 peptides and vaccines
|
WO2012138377A2
(en)
|
2010-10-01 |
2012-10-11 |
Trustees Of The University Of Pennsylvania |
The use of listeria vaccine vectors to reverse vaccine unresponsiveness in parasitically infected individuals
|
WO2012069466A1
(en)
|
2010-11-24 |
2012-05-31 |
Novartis Ag |
Multispecific molecules
|
SG191153A1
(en)
|
2010-12-23 |
2013-07-31 |
Hoffmann La Roche |
Polypeptide-polynucleotide-complex and its use in targeted effector moiety delivery
|
EP2683400A4
(en)
|
2011-03-11 |
2014-09-17 |
Advaxis |
ADJUVANZIA ON LISTERIA BASE
|
EP2744824A1
(en)
|
2011-08-17 |
2014-06-25 |
F.Hoffmann-La Roche Ag |
Neuregulin antibodies and uses thereof
|
SG11201400432VA
(en)
|
2011-09-06 |
2014-08-28 |
Agency Science Tech & Res |
Polypeptide vaccine
|
KR102679155B1
(ko)
|
2011-10-14 |
2024-06-28 |
제넨테크, 인크. |
Her2 이량체화 억제제인 페르투주맙의 용도 및 이를 포함하는 제조품
|
WO2013063229A1
(en)
|
2011-10-25 |
2013-05-02 |
The Regents Of The University Of Michigan |
Her2 targeting agent treatment in non-her2-amplified cancers having her2 expressing cancer stem cells
|
SG11201402510TA
(en)
|
2011-11-30 |
2014-06-27 |
Genentech Inc |
Erbb3 mutations in cancer
|
US9376715B2
(en)
|
2011-12-09 |
2016-06-28 |
Roche Molecular Systems, Inc |
Methods for detecting mutations in the catalytic subunit of the phosphoinositol-3 kinase (PIK3CA) gene
|
SG11201405605VA
(en)
|
2012-03-12 |
2014-10-30 |
Advaxis Inc |
SUPPRESSOR CELL FUNCTION INHIBITION FOLLOWING <i>LISTERIA</i> VACCINE TREATMENT
|
EP2831115A1
(en)
|
2012-03-27 |
2015-02-04 |
F. Hoffmann-La Roche AG |
Diagnosis and treatments relating to her3 inhibitors
|
AU2013262934B2
(en)
|
2012-05-14 |
2018-02-01 |
Biogen Ma Inc. |
LINGO-2 antagonists for treatment of conditions involving motor neurons
|
WO2014031178A1
(en)
|
2012-08-24 |
2014-02-27 |
Etubics Corporation |
Replication defective adenovirus vector in vaccination
|
JP6998646B2
(ja)
|
2012-11-30 |
2022-02-04 |
エフ・ホフマン-ラ・ロシュ・アクチェンゲゼルシャフト |
Pd-l1阻害剤併用療法を必要とする患者の同定
|
WO2014127296A1
(en)
|
2013-02-14 |
2014-08-21 |
Immunocellular Therapeutics, Ltd |
Cancer vaccines and vaccination methods
|
EP2777711A1
(en)
*
|
2013-03-11 |
2014-09-17 |
Icon Genetics GmbH |
Her2/Neu cancer vaccine
|
KR20200085942A
(ko)
|
2013-04-16 |
2020-07-15 |
제넨테크, 인크. |
페르투주맙 변이체 및 그의 평가
|
WO2015138435A1
(en)
|
2014-03-11 |
2015-09-17 |
Molecular Templates, Inc. |
Proteins comprising binding regions, shiga toxin a subunit effector regions, and carboxy-terminal, endoplasmic reticulum localization signal motifs
|
EP3604333B1
(en)
|
2014-03-11 |
2021-05-05 |
Molecular Templates, Inc. |
Proteins comprising amino-terminal proximal shiga toxin a subunit effector regions and cell-targeting immunoglobulin-type binding regions capable of specifically binding cd38
|
SG10201809411PA
(en)
|
2014-04-25 |
2018-11-29 |
Genentech Inc |
Methods of treating early breast cancer with trastuzumab-mcc-dm1 and pertuzumab
|
JP2018504400A
(ja)
|
2015-01-08 |
2018-02-15 |
バイオジェン・エムエイ・インコーポレイテッドBiogen MA Inc. |
Lingo‐1拮抗薬及び脱髄障害の治療のための使用
|
EP3302551B1
(en)
|
2015-05-30 |
2024-06-26 |
F. Hoffmann-La Roche AG |
Methods of treating her2-positive previously untreated metastatic breast cancer
|
MX2017015493A
(es)
|
2015-05-30 |
2018-02-09 |
Molecular Templates Inc |
Andamiajes de la subunidad a de la toxina shiga desinmunizados y moleculas con direccion a las celulas que los comprenden.
|
JP6884133B2
(ja)
|
2015-07-26 |
2021-06-09 |
モレキュラー テンプレーツ, インク.Molecular Templates, Inc. |
志賀毒素aサブユニットエフェクター及びcd8+t細胞エピトープを含む細胞標的化分子
|
WO2017087280A1
(en)
|
2015-11-16 |
2017-05-26 |
Genentech, Inc. |
Methods of treating her2-positive cancer
|
WO2017194554A1
(en)
|
2016-05-10 |
2017-11-16 |
Inserm (Institut National De La Sante Et De La Recherche Medicale) |
Combinations therapies for the treatment of cancer
|
TW201818940A
(zh)
|
2016-11-04 |
2018-06-01 |
美商建南德克公司 |
Her2陽性乳癌之治療
|
JP6914336B2
(ja)
|
2016-12-28 |
2021-08-04 |
ジェネンテック, インコーポレイテッド |
進行したher2発現がんの治療
|
CR20190376A
(es)
|
2017-01-17 |
2019-11-20 |
Genentech Inc |
Formulaciones de anticuerpos de her2 subcutáneas
|
US20200024312A1
(en)
|
2017-01-25 |
2020-01-23 |
Molecular Templates, Inc. |
Cell-targeting molecules comprising de-immunized, shiga toxin a subunit effectors and cd8+ t-cell epitopes
|
HRP20240069T1
(hr)
|
2017-03-02 |
2024-03-29 |
Genentech, Inc. |
Adjuvantno liječenje her2-pozitivnog raka dojke
|
AU2018258263A1
(en)
|
2017-04-24 |
2019-10-24 |
Genentech, Inc. |
ErbB2/Her2 mutations in the transmembrane or juxtamembrane domain
|
IL268443B2
(en)
|
2018-04-17 |
2024-07-01 |
Molecular Templates Inc |
HER2-targeted molecules containing Shiga toxin subunit A scaffolds, without vaccination
|